RadioMedix and AREVA Med Awarded SBIR NCI Contract to Develop Targeted Alpha-Emitter Therapy of Neuroendocrine Tumors with Lead-212

RadioMedix Inc. and AREVA Med have been awarded a collaborative Small Business Innovation Research (SBIR) Contract Grant by the National Institutes of Health, National Cancer Institute to evaluate targeted alpha-emitter therapy of neuroendocrine tumors (NETs). This is the fourth NIH grant awarded to RadioMedix during the last three years.

Targeted Peptide Receptor Radio Therapy (PRRT) of NETs is one of the main clinical focuses of RadioMedix, which has long been involved in  several clinical studies as a co-sponsor or a collaborator. AREVA Med is focused on the production of lead-212 (²¹²Pb), a rare metal used in TAT, and the development of therapeutics using this metal.

“We have established a very good collaboration with AREVA Med and we are very pleased that this work resulted in the SBIR grant award,” said Izabela Tworowska PhD, Principal Investigator and RadioMedix Chief Science Officer.” We have got promising preliminary results and we are confident that this grant award will accelerate the development of Targeted Alpha Therapy (TAT) agents. I am grateful to NIH NCI agency for selecting this project for funding”

 “AREVA Med is very excited about its collaboration with RadioMedix  that will further support the growth of our pipeline of ²¹²Pb-labeled agents, especially in NETs where we believe we can bring substantial additional efficacy compared to current treatment options” said Julien Torgue, PhD, AREVA Med Scientific Director.

 “We are confident that we have secured all resources needed to accelerate translation of targeted alpha therapy agents to clinic,” said Dr. Ebrahim Delpassand, CEO and Chairman of RadioMedix. “Our patients are anxiously waiting for this treatment, and we expect to launch a first in human clinical trial by the end of 2017.”